RxDoctor Payments Data

Priyank Chauhan, MD

Geriatric Medicine · Leitchfield, KYNPI 1093200602

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $684, more than ten times the $31 reported in 2022.

$797in general payments, 2019–2025

Across 50 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$168
  • Phathom Pharmaceuticals, Inc.$103
  • AbbVie$97
  • Amgen$72
  • Lilly USA, LLC$52
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$51
  • plus $254 from 11 others

What the payments were for

  • Food & beverage$797100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$797 in reported general payments places this provider in the 65th percentile of 33 geriatric medicine providers in Kentucky.

See all geriatric medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$79,019
Medicare patients
220
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban19$17,103
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,122
Cefpodoxime Proxetil55$1,891
Pantoprazole Sodium73$948
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav83$384
Bumetanide13$306
Amlodipine Besylate48$215
Famotidine12$210
Atorvastatin Calcium28$181
Furosemide29$116
Prednisone74$104
Metoprolol Tartrate19$93
Losartan Potassium15$73
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$56
Doxycycline Hyclate13$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$17,10319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 geriatric medicine providers in Kentucky.

Other geriatric medicine in Leitchfield

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →